1<p>Two or more oligoclonal bands in CSF at isoelectric focusing that were not present in serum.</p>2<p>Number of weeks after treatment starts when blood samples were taken.</p>3<p>Patient 2 had previously used interferon-β1a treatment, the others were treatment naive.</p><p>Abbreviations: GA = glatiramer acetate, M = Male, F = Female, ON = Optic Neuritis, EDSS = Expanded disability status scale, OCB = Oligoclonal Bands, ND = No data.</p
BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring ...
Background and Purpose: Early relapse outcomes in long-term stable patients switching from interfero...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...
a<p>Median number of years from first symptoms of MS to inclusion.</p>b<p>Treatment within 4 months ...
There are few long-term clinical and magnetic resonance imaging (MRI) data on patients treated with ...
Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant ...
Background: Prognostic markers are needed to guide multiple sclerosis (MS) management in the context...
The aim of this study is to compare the white matter of multiple sclerosis (MS) patients with health...
Background The increase in disease-modifying drugs (DMDs) allows individualization of treatment in r...
Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of centr...
BACKGROUND: Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or...
To assess the role of CSF oligoclonal bands (OB) in determining the clinical outcome in patients wit...
BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitor...
OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous resp...
BACKGROUND: Interferon beta reduces activity in multiple sclerosis as measured clinically and by mag...
BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring ...
Background and Purpose: Early relapse outcomes in long-term stable patients switching from interfero...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...
a<p>Median number of years from first symptoms of MS to inclusion.</p>b<p>Treatment within 4 months ...
There are few long-term clinical and magnetic resonance imaging (MRI) data on patients treated with ...
Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant ...
Background: Prognostic markers are needed to guide multiple sclerosis (MS) management in the context...
The aim of this study is to compare the white matter of multiple sclerosis (MS) patients with health...
Background The increase in disease-modifying drugs (DMDs) allows individualization of treatment in r...
Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of centr...
BACKGROUND: Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or...
To assess the role of CSF oligoclonal bands (OB) in determining the clinical outcome in patients wit...
BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitor...
OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous resp...
BACKGROUND: Interferon beta reduces activity in multiple sclerosis as measured clinically and by mag...
BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring ...
Background and Purpose: Early relapse outcomes in long-term stable patients switching from interfero...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...